154 related articles for article (PubMed ID: 32646834)
1. The Use of 20% Subcutaneous Immunoglobulin Replacement Therapy in Patients With B Cell Non-Hodgkin Lymphoma With Humoral Immune Dysfunction After Treatment With Rituximab.
Mustafa SS; Jamshed S; Vadamalai K; Ramsey A
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):e590-e596. PubMed ID: 32646834
[TBL] [Abstract][Full Text] [Related]
2. Infectious diseases and immunological markers associated with patients with non-Hodgkin lymphoma treated with rituximab.
de Souza KJ; Ferro RS; Prestes-Carneiro LE; Carrilho PAM; Vasconcelos DM
Immunopharmacol Immunotoxicol; 2018 Feb; 40(1):13-17. PubMed ID: 29094629
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous immunoglobulin replacement for treatment of humoral immune dysfunction in patients with chronic lymphocytic leukemia.
Mustafa SS; Jamshed S; Vadamalai K; Ramsey A
PLoS One; 2021; 16(10):e0258529. PubMed ID: 34653210
[TBL] [Abstract][Full Text] [Related]
4. B cell subsets reconstitution and immunoglobulin levels in children and adolescents with B non-Hodgkin lymphoma after treatment with single anti CD20 agent dose included in chemotherapeutic protocols: single center experience and review of the literature.
Hlavackova E; Krenova Z; Kerekes A; Slanina P; Vlkova M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2024 Jun; 168(2):167-176. PubMed ID: 37227099
[TBL] [Abstract][Full Text] [Related]
5. Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial.
Alexander S; Aupérin A; Bomken S; Csóka M; Kazanowska B; Chiang AK; Andres M; Uyttebroeck A; Burke GAA; Zsiros J; Pillon M; Bollard CM; Mussolin L; Verdu-Amoros J; Neven B; Barkauskas DA; Wheatley K; Patte C; Gross TG; Minard-Colin V; ;
Lancet Haematol; 2023 Jun; 10(6):e445-e457. PubMed ID: 37094596
[TBL] [Abstract][Full Text] [Related]
6. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
Piro LD; White CA; Grillo-López AJ; Janakiraman N; Saven A; Beck TM; Varns C; Shuey S; Czuczman M; Lynch JW; Kolitz JE; Jain V
Ann Oncol; 1999 Jun; 10(6):655-61. PubMed ID: 10442187
[TBL] [Abstract][Full Text] [Related]
7. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
8. A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma.
Torka P; Patel P; Tan W; Wilding G; Bhat SA; Czuczman MS; Lee KP; Deeb G; Neppalli V; Mavis C; Wallace P; Hernandez-Ilizaliturri FJ
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e51-e60. PubMed ID: 29233743
[TBL] [Abstract][Full Text] [Related]
9. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.
Bingham CO; Looney RJ; Deodhar A; Halsey N; Greenwald M; Codding C; Trzaskoma B; Martin F; Agarwal S; Kelman A
Arthritis Rheum; 2010 Jan; 62(1):64-74. PubMed ID: 20039397
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and predictors of infusion-related reactions to rituximab in patients with B-cell non-Hodgkin lymphoma.
Faqeer N; Alrabie R; Al-Haddadin R; Ma'koseh M
J Chemother; 2024 Jul; 36(4):291-298. PubMed ID: 37860948
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine.
Kapetanovic MC; Nagel J; Nordström I; Saxne T; Geborek P; Rudin A
Vaccine; 2017 Feb; 35(6):903-908. PubMed ID: 28081972
[TBL] [Abstract][Full Text] [Related]
12. An Immune Recovery-Based Revaccination Protocol for Pediatric Hematopoietic Stem Cell Transplant Recipients: Revaccination Outcomes Following Pediatric HSCT.
Haynes AS; Curtis DJ; Campbell K; Giller RH; Quinones RR; Verneris MR; Abzug MJ
Transplant Cell Ther; 2021 Apr; 27(4):317-326. PubMed ID: 33836875
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation.
Kaya H; Keung YK; Case D; Cruz JM; Perry JJ; Radford JE; Hurd DD
Biol Blood Marrow Transplant; 2002; 8(10):544-9. PubMed ID: 12434949
[TBL] [Abstract][Full Text] [Related]
14. Enteroviral infection in patients treated with rituximab for non-Hodgkin lymphoma: a case series and review of the literature.
Grisariu S; Vaxman I; Gatt M; Elias S; Avni B; Arad A; Pasvolsky O; Raanani P; Paltiel O
Hematol Oncol; 2017 Dec; 35(4):591-598. PubMed ID: 27734521
[TBL] [Abstract][Full Text] [Related]
15. Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
Advani RH; Lebovic D; Chen A; Brunvand M; Goy A; Chang JE; Hochberg E; Yalamanchili S; Kahn R; Lu D; Agarwal P; Dere RC; Hsieh HJ; Jones S; Chu YW; Cheson BD
Clin Cancer Res; 2017 Mar; 23(5):1167-1176. PubMed ID: 27601593
[No Abstract] [Full Text] [Related]
16. Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort.
Desai AK; Baloh CH; Sleasman JW; Rosenberg AS; Kishnani PS
Front Immunol; 2020; 11():1727. PubMed ID: 32849613
[TBL] [Abstract][Full Text] [Related]
17. The role of BAFF and G-CSF for rituximab-induced late-onset neutropenia (LON) in lymphomas.
Tesfa D; Sander B; Lindkvist H; Nilsson C; Kimby E; Hägglund H; Wahlin BE; Klimkowska M; Palmblad J
Med Oncol; 2021 May; 38(6):70. PubMed ID: 34003398
[TBL] [Abstract][Full Text] [Related]
18. Parasitic infections during pregnancy need not affect infant antibody responses to early vaccination against Streptococcus pneumoniae, diphtheria, or Haemophilus influenzae type B.
McKittrick ND; Malhotra IJ; Vu DM; Boothroyd DB; Lee J; Krystosik AR; Mutuku FM; King CH; LaBeaud AD
PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007172. PubMed ID: 30818339
[TBL] [Abstract][Full Text] [Related]
19. Fulminant hepatitis B as a result of reactivation in hematologic patient after rituximab therapy.
Yilmaz B
J Med Virol; 2016 Aug; 88(8):1289-90. PubMed ID: 27249067
[No Abstract] [Full Text] [Related]
20. Type-specific anti-pneumococcal antibody subclass response to vaccination after splenectomy with special reference to lymphoma patients.
Grimfors G; Björkholm M; Hammarström L; Askergren J; Smith CI; Holm G
Eur J Haematol; 1989 Nov; 43(5):404-10. PubMed ID: 2612613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
